The FDA is in the midst of a significant transition as it pivots from using Anthropic’s Claude AI model to Google’s Gemini, following a directive from President Trump. This shift, prompted by security concerns regarding AI in defense, poses risks for life sciences sponsors as the migration is expected to be rapid and lacking transparency. Elsa, the FDA’s AI assistant, is not just a simple chatbot; it’s a complex system tailored for regulatory review. The shift necessitates reengineering the entire AI data pipeline, which raises legal and compliance issues, particularly regarding data handling policies and administrative record integrity. Sponsors should take immediate action to protect confidential information by reevaluating disclosure practices, seeking clear assurances on data handling post-migration, documenting all communications, and staying informed about changes in the AI model used during submissions. The FDA’s forced transition marks a crucial development in AI regulation, requiring sponsors to tread carefully through this evolving landscape.
Source link
